Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Blaze Bioscience Australia Pty Ltd
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients age ≥ 18 years.
Known or suspected non-metastatic basal cell or squamous cell carcinomas ≥10 mm longest diameter or non-metastatic melanoma ≥6 mm longest diameter scheduled for excision, without advanced disease.
Written Informed Consent.
Agree to the use of effective contraceptive from Baseline and for 30 days after treatment if either male or female of child bearing potential.
Available for and able to comply with study requirements.
You may not be if
Women who are lactating/breastfeeding
Women with a positive pregnancy test or who are planning to become pregnant during the duration of the study.
Life expectancy \<6 months.
Karnofsky Performance Status of ≤70%.
The following laboratory abnormalities:
* Neutrophil count \<1.5 x 10\^9/L
* Platelets \<75 x 10\^9/L
* Haemoglobin \<10 g/dL (may be determined following transfusion)
* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2x upper limit of normal (ULN)
* Total bilirubin \>2x upper limit of reference range (unless Gilbert's syndrome or extrahepatic source as denoted by increased indirect bilirubin fraction)
* International Normalized Ratio (INR) \>1.5
* Creatinine \>1.5x ULN
History of hypersensitivity or allergic reactions requiring corticosteroids, epinephrine and/or hospitalization.
Uncontrolled asthma or asthma requiring oral corticosteroids.
Clinically significant chronic inflammatory skin conditions, including psoriasis, atopic dermatitis and scleroderma, as determined by the investigator.
Unstable angina, myocardial infarction, known or suspected transient ischemic events or stroke within 24 weeks of Screening.
Receipt of photosensitising drugs within 30 days of screening.
Positive serology for human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV).
Any concurrent condition, including psychological and social situations, which, in the opinion of the investigator, would impact adversely on the subject or the interpretation of the study data.
Known or suspected sensitivity to study product or excipients.
Prior participation in this clinical trial (has received study product).
Clareo Health | Safety Study of a Fluorescent Marker to Visualize Cancer Cells
